Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Increases By 1,920.0%

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 10,100 shares, an increase of 1,920.0% from the December 31st total of 500 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 21,600 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO opened at $4.01 on Wednesday. The stock has a market capitalization of $6.18 million, a PE ratio of -1.51 and a beta of 2.22. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The business’s fifty day moving average price is $4.17 and its 200-day moving average price is $4.00.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The business had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. As a group, equities analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.